Skip to content

Ketamine: all studies

Page 349 of 448: studies 3,481 to 3,490 of 4,475, newest first. Back to the ketamine overview

Research

Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy.

Frontiers in Psychiatry 2015 Charles F Zorumski, Peter Nagele, Steven Mennerick et al.

Major depressive disorder (MDD) remains a huge personal and societal encumbrance. Particularly burdensome is a virulent subtype of MDD, treatment resistant major depression (TMRD), which afflicts 15-30% of MDD patients. There has been recent interest in N-methyl-d-aspartate receptors (NMDARs) as targets for treatment of MDD and perhaps TMRD. To date, most pre-clinical and clinical studies have...

Can psychedelic compounds play a part in drug dependence therapy?

The British Journal of Psychiatry 2015 Ben Sessa, Matthew W. Johnson 58 citations

Summary After a 40-year hiatus there is now a revisiting of psychedelic drug therapy throughout psychiatry, with studies examining the drugs psilocybin, ketamine, ibogaine and ayahuasca in the treatment of drug dependence. Limitations to these therapies are both clinical and legal, but the possibility of improving outcomes for patients with substance dependency imposes an obligation to research...

Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine.

Clinical Toxicology December 1, 2014 Katharina E Hofer, Colette Degrandi, Daniel Müller et al.

Methoxphenidine is a novel dissociative designer drug of the diarylethylamine class which shares structural features with phencyclidine (PCP), and is not at present subject to restrictive regulations. There is very limited information about the acute toxicity profile of methoxphenidine and the only sources are anonymous internet sites and a 1989 patent of the Searle Company. We report a case of...

Neural Correlates of Suicidal Ideation and Its Reduction in Depression

The International Journal of Neuropsychopharmacology October 31, 2014 Elizabeth D. Ballard, Níall Lally, Allison C. Nugent et al. 74 citations

BACKGROUND: The neural correlates of suicidal ideation and its reduction after treatment are unknown. We hypothesized that increased regional cerebral glucose metabolism in the infralimbic cortex (Brodmann area 25), amygdala, and subgenual anterior cingulate cortex would be associated with suicidal ideation and its reduction after ketamine infusion. METHODS: Medication-free patients (n=19) with...

DOI: 10.1093/ijnp/pyu069 (opens in new tab) Full text (opens in new tab) Ketamine Suicidal ideation Anterior cingulate cortex Infralimbic cortex +8

NEUROBIOLOGY OF STRESS, DEPRESSION, AND RAPID ACTING ANTIDEPRESSANTS: REMODELING SYNAPTIC CONNECTIONS

Depression and Anxiety March 10, 2014 Ronald S. Duman 213 citations

Stress and depression are associated with atrophy and loss of neurons in limbic and cortical brain regions that could contribute to the symptoms of depression. Typical monoamine reuptake inhibitor antidepressants have only modest efficacy and require long-term treatment, and are only weakly effective in blocking or reversing these structural changes caused by stress. Recent findings demonstrate...

Drug Abuse and Cardiac Problem

Medicine Today February 10, 2014 Mohammad Shafiqur Rahman Patwary, Kazi Abdullah Al Mamun 4 citations

Drug abuse has reached epidemic proportions in many countries including Bangladesh and threatens to overwhelm economic, social, and health care systems. In addition to their effects on the central nervous system, many of these agents induce profound changes in the heart and circulation that are responsible for a significant proportion of drug-related morbidity. Drugs that can affect the...

From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs.

Drug Testing and Analysis 2014 Hamilton Morris, Jason Wallach 240 citations

PCP or phencyclidine was discovered in 1956 and soon became a popular street drug. Dissociatives including PCP, ketamine, and dextromethorphan have been used non-medically for their mind-altering effects for over 60 years. Many of these compounds have also been used clinically and in legitimate research. At least 14 derivatives of PCP were sold for non-medical and illict use from the late 1960s...

Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects

Molecular Psychiatry October 15, 2013 Gerard Sanacora, Mark A. Smith, Sanjeev Pathak et al. 234 citations

Ketamine, an N-methyl-D-aspartate receptor (NMDAR) channel blocker, has been found to induce rapid and robust antidepressant-like effects in rodent models and in treatment-refractory depressed patients. However, the marked acute psychological side effects of ketamine complicate the interpretation of both preclinical and clinical data. Moreover, the lack of controlled data demonstrating the...

mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure

Journal of Molecular Psychiatry September 17, 2013 Jason M. Dwyer, Ashley E. Lepack, Ronald S. Duman 81 citations

BACKGROUND: Depression is a prevalent neuropsychiatric disorder that affects an estimated 350 million people worldwide. Currently available treatments for depression are lacking in both speed of onset and efficacy. Recent pharmacological efforts have targeted the glutamatergic neurotransmitter system using the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine to produce rapid and robust...

DOI: 10.1186/2049-9256-1-15 (opens in new tab) Ketamine Anhedonia Antidepressant Metabotropic glutamate receptor +8

Family history of alcohol dependence and antidepressant response to an N‐methyl‐D‐aspartate antagonist in bipolar depression

Bipolar Disorders September 14, 2012 David A. Luckenbaugh, Lobna Ibrahim, Nancy E. Brutsché et al. 69 citations

Luckenbaugh DA, Ibrahim L, Brutsche N, Franco‐Chaves J, Mathews D, Marquardt CA, Cassarly C, Zarate CA Jr. Family history of alcohol dependence and antidepressant response to an N ‐methyl‐ d ‐aspartate antagonist in bipolar depression. Bipolar Disord 2012: 14: 880–887. Published 2012. This article is a U.S. Government work and is in the public domain in the USA. Objectives: Both ketamine and...